Position of the Transparency Council – Ilaris (canakinumab)

At its meeting on 22 July 2024, the Transparency Council adopted position No. 75/2024 on the evaluation of the drug Ilaris (canakinumab) for the indication: “Treatment of patients with rheumatoid arthritis and juvenile idiopathic arthritis (ICD 10: M05, M06, M08)”

Publication of the position >>